Enliven Therapeutics (ELVN) Accumulated Depreciation (2019 - 2026)

Enliven Therapeutics has disclosed Accumulated Depreciation across 8 years of filings, most recently posting $243000.0 for Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $243000.0, down 75.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $243000.0 (down 75.53% YoY), and the FY2025 annual result was $229000.0, down 75.08% from the prior year.
• Accumulated Depreciation came in at $243000.0 for Q1 2026 at Enliven Therapeutics, up from $229000.0 in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $1.1 million in Q3 2025 to a low of $229000.0 in Q4 2025.
• The 5-year median for Accumulated Depreciation is $710500.0 (2023), against an average of $691000.0.
• Across the five-year window, Accumulated Depreciation surged 79.41% in 2023 and plunged 75.53% in 2026, its largest moves.
• Enliven Therapeutics' Accumulated Depreciation stood at $374000.0 in 2022, then surged by 79.41% to $671000.0 in 2023, then surged by 36.96% to $919000.0 in 2024, then plunged by 75.08% to $229000.0 in 2025, then increased by 6.11% to $243000.0 in 2026.
• The last three Accumulated Depreciation figures came in at $243000.0 (Q1 2026), $229000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.